Other
Aggressive Periodontitis
10
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
Aggressive Periodontitis is an early-stage landscape with 10 programs across 3 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Bayer, AbbVie. 3 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 33
Analysis
Trial Status
12
clinical trials
Completed10 · 83%
Unknown status2 · 17%
Clinical Trials
Trial Activity
12 trials
Host Modulatory Effects of β-glucan on Localized Aggressive Periodontitis
Completed·—·Phase 4·NCT02402296·30 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)